Immunome to Present at the Stifel 2023 Healthcare Conference
- Immunome's participation in the Stifel 2023 Healthcare Conference indicates industry recognition and potential networking opportunities for the company and its CEO.
- The focus on developing first-in-class and best-in-class targeted cancer therapies demonstrates Immunome's commitment to innovation and addressing unmet medical needs in the oncology space.
- None.
Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company’s website at www.immunome.com. The webcast replay will be available after the conclusion of the live presentation for approximately 90 days.
About Immunome, Inc.
Immunome is a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies. Our portfolio pursues each target with a modality appropriate to its biology, including immunotherapies, targeted effectors, radioligand therapies and ADCs. We believe that pursuing underexplored targets with appropriate drug modalities leads to transformative therapies. Our proprietary memory B cell hybridoma technology allows for the rapid screening and functional characterization of novel antibodies and targets.
For more information, visit www.immunome.com or follow us on Twitter and LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231110745339/en/
Investor Contact
Corleen Roche
Chief Financial Officer
investors@immunome.com
Media Contact
Andrew W. Mielach
LifeSci Communications
amielach@lifescicomms.com
Source: Immunome, Inc.
FAQ
What is the latest announcement from Immunome, Inc. (IMNM)?
When and where will the presentation take place?
How long will the webcast be available for replay?
